Immuneering (IMRX) Operating Leases (2020 - 2026)

Immuneering's Operating Leases history runs 7 years deep, the most recent figure standing at $3.7 million for Q1 2026.

• In Q1 2026, Operating Leases fell 8.63% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $3.7 million (down 8.63% YoY), while the FY2025 annual figure was $3.4 million, down 10.38% from the prior year.
• Operating Leases was $3.7 million for Q1 2026 at Immuneering, up from $3.4 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $4.7 million in Q1 2023 to a low of $3.4 million in Q4 2025.
• Historically, Operating Leases has averaged $4.2 million across 5 years, with a median of $4.3 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Operating Leases jumped 842.53% in 2022, then retreated 15.73% in 2025.
• A 5-year view of Operating Leases shows it stood at $4.5 million in 2022, then retreated by 6.72% to $4.2 million in 2023, then declined by 8.13% to $3.8 million in 2024, then fell by 10.38% to $3.4 million in 2025, then grew by 8.84% to $3.7 million in 2026.
• The last three Operating Leases figures came in at $3.7 million (Q1 2026), $3.4 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.